Top

Diabetology International

Published in:

01-12-2011 | Original article

Converse contributions of fasting and postprandial glucose to HbA_1c and glycated albumin

Authors: Nobuko Sakuma, Masao Omura, Eisei Oda, Toshikazu Saito

Published in: Diabetology International | Issue 4/2011

Abstract

Objective

We evaluated the relationship between glycated hemoglobin (HbA_1c) in diabetic patients with stable glycemic control and the average fasting blood glucose (FBG) and postprandial blood glucose (PPG) values of 4 weeks prior to HbA_1c measurement and compared the results with glycated albumin (GA).

Research design and methods

Fifty-one diabetic patients were asked to use self-monitoring blood glucose to measure FBG before breakfast and PPG 1 and 2 h after breakfast 1 day a week for 4 weeks while maintaining normal daily activities. During monthly outpatient visits, HbA_1c and GA were measured. Data were analyzed in 40 patients, with <1% variation in HbA_1c values over 4 months.

Results

HbA_1c was best predicted by the average FBG (AvFBG) and the average of 1-h and 2-h PPG (AvMPPG) (adjusted R ² = 0.51; HbA_1c = 4.35 + 0.013 AvFBG + 0.0056 AvMPPG). The contribution ratio was 0.013:0.0056, showing about 2.3 times greater contribution by FBG. GA was best predicted by the AvFBG and the average of 2-h PPG (Av2hPPG) (adjusted R ² = 0.55; GA = 9.36 + 0.0241 AvFBG + 0.0430 Av2hPPG). The contribution ratio was 0.024:0.043, showing about 1.8 times greater contribution by 2-h PPG. This converse contribution of fasting and postprandial glucose to HbA_1c and GA was more prominent in insulin-treated patients than in untreated patients.

Conclusions

HbA_1c and GA can be satisfactorily predicted by FBG and PPG. HbA_1c reflects FBG more so than PPG, whereas GA better reflects PPG. Thus, depending on the characteristics of the glycated protein, a different glycemic status is reflected.

Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577–83.PubMedCrossRef

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617–621.

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.PubMedCrossRef

Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822–6.PubMedCrossRef

Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose levels throughout the day and HbA_1C interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001;24:2023–9.PubMedCrossRef

Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA_1C. Diabetes Care. 2003;26:881–5.PubMedCrossRef

Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA_1C affected by glycemic instability? Diabetes Care. 2003;26:2728–33.PubMedCrossRef

Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001;24:1858–62.PubMedCrossRef

Salardi S, Zucchini S, Santoni R, Ragni L, Gualandi S, Cicognani A, Cacciari E. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA_1C in pediatric type 1 diabetic patients. Diabetes Care. 2002;25:1840–4.PubMedCrossRef

10.

Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;77:420–6.PubMedCrossRef

11.

Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y, Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896–903.PubMedCrossRef

12.

Hashimoto K, Noguchi S, Morimoto Y, Hamada S, Wasada K, Imai S, Murata Y, Kasayama S, Koga M. A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care. 2008;31:1945–8.PubMedCrossRef

13.

Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18:440–7.PubMedCrossRef

14.

Takahashi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, Watada H, Hirose T, Kawamori R, Tanaka Y. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J. 2007;54:139–44.PubMedCrossRef

15.

Kouzuma T, Uemastu Y, Usami T, Imamura S. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clinical Chimca Acta. 2004;346:135–43.CrossRef

16.

Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P, Meigs JB. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia. 2006;49:846–54.PubMedCrossRef

17.

Borg R, Kuenen J, Carstensen B, Zheng H, Nathan D, Heine R, Nerup J, Johnsen K, Witte D, on behalf of the ADAG study Group. Associations between features of glucose exposure and A1C, the A1C-Derived Average Glucose (ADAG) Study. Diabetes. 2011;54(1):69–72.

18.

Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, Matsuoka T, Umayahara Y, Kosugi K, Kaneto H, Yamasaki Y, Hori M. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. 2008;55:503–7.PubMedCrossRef

19.

Koga M, Murai J, Saito H, Kasayama S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care. 2010;33:270–2.PubMedCrossRef

20.

Suwa T, Ohta A, Matsui T, Koganei R, Kato H, Kawata T, Sada Y, Ishii S, Kondo A, Murakami K, Katabami T, Tanaka Y. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J. 2010;57:135–40.PubMedCrossRef

21.

Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30:263–9.PubMedCrossRef

22.

Monnier L, Colette C, Rabasa-Lhoret R, Lapinski H, Caubel C, Avignon A, Boniface H. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care. 2002;25:737–41.PubMedCrossRef

23.

Day JF, Ingebretsen CG, Ingebretsen WR Jr, Baynes JW, Thorpe SR. Nonenzymatic glucosylation of serum proteins and hemoglobin: response to changes in blood glucose levels in diabetic rats. Diabetes. 1980;29:524–7.PubMedCrossRef

Title: Converse contributions of fasting and postprandial glucose to HbA1c and glycated albumin
Authors: Nobuko Sakuma
Masao Omura
Eisei Oda
Toshikazu Saito
Publication date: 01-12-2011
Publisher: Springer Japan
Published in: Diabetology International / Issue 4/2011
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-011-0036-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Research design and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

Prevention of disaster

Cases with Hb Toranomon show abnormal HbA1c levels measured by upgraded high-performance liquid chromatography models

Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects

A single-nucleotide polymorphism in the human THADA gene is associated with circulating resistin in the general Japanese population

A case of type 2 diabetes with polymyalgia rheumatica accompanied by marked prothrombin time-international normalized ratio elongation

Administration of insulin glargine thrice weekly by medical staff at a dialysis unit: a new insulin regimen for diabetic management in physically impaired patients undergoing hemodialysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials